Jubilant Therapeutics

“Jubilant’s Precision Medicines Offer Safety, Therapeutic Advantages in Cancer, Immunology” in @BioSpace discusses our innovative pipeline targeting oncology & immunology, TIBEO discovery engine, & interest in strategic partnerships. bit.ly/3JnDSfr

Welcome our newest independent member of our Board of Directors, Mr. Nadir Patel. He has had a notable career in government affairs & advising corporate execs. We’re thrilled to have such a seasoned strategist assisting us as we progress our drug pipeline. bit.ly/3qP5oMI

We’re at @ASCO! Today is the first day of the Annual Meeting in Chicago and we are excited to network with our peers. Please reach out to us at BD@jubilanttx.com if you are attending and would like to discuss our research. #ASCO23

Jubilant Therapeutics is attending @IAmBiotech International Convention next week in Boston. Our team is available for one-on-one meetings to discuss our pipeline and can be scheduled using the partnering link below or email BD@jubilanttx.com. #BIO23 bit.ly/3o4afbz

Jubilant Therapeutics is attending @ASCO Annual Meeting in two weeks in Chicago. Various members of our team will be present and are eager to connect with fellow oncology innovators. To connect in person, email BD@jubilanttx.com.

CEO, Syed Kazmi, Ph.D., is pleased to be attending @IAmBiotech International Convention and have the opportunity to network with thousands of biotech and pharma leaders. Dr. Kazmi is available for 1-on-1s to discuss our differentiated pipeline. To partner: bit.ly/3o4afbz

Jubilant Therapeutics is attending @ASCO Annual Meeting 2023 on June 2-6 in Chicago. Dr. Rastelli, CSO, Dr. Rajagopal, VP & Head of Medicinal Chemistry, and Mr. Krishnan, Associate Director, BD, are excited to connect with our colleagues also working in the oncology field.#ASCO23

Jubilant Therapeutics is attending @IAmBiotech International Convention & is available for partnering. We look forward to discussing our differentiated, orally bioavailable clinical & preclinical programs targeting oncology & autoimmune disease. To partner bit.ly/3o4afbz

CEO, Dr. Syed Kazmi, is attending #BioEquity 5/14-16 in Dublin and is available for partnering. Our precision #biotech company is compiled of differentiated drug candidates for challenging diseases in #oncology and #autoimmunediseases. Come talk with Dr. Kazmi to learn more.

CEO, Syed Kazmi, Ph.D., spoke with Investment Reports, a @Newsweek provider, about the history of Jubilant Therapeutics, our areas of expertise in the industry, our TIBEO discovery engine helps achieve pipeline goals, & our priorities for the near future. bit.ly/446i29h

Dr. Luca Rastelli & other members of the team present data on our brain penetrant small molecule PRMT5 inhibitor JBI-778 for the treatment of cancer @AACR Annual Meeting today. Stop by our poster presentation from 9am-12:30pm EDT in Section 20. Abstract:bit.ly/40b8maq

Today our CEO, Syed Kazmi, Ph.D., and CFO, Shyam Pattabiraman, are presenting at @BioNJ_Org BioPartnering Conference from 2:45-4:30pm EDT. If you are attending the conference, please stop by our presentation and learn about Jubilant Therapeutics! #BioNJ #BioP2023

Our CFO, Shyam Pattabiraman is presenting @BioNJ_Org BioPartnering Conference on April 18th and is also available for partnering. Please do catch-up with our presentation between 2:45pm to 4:30pm Schedule here: bit.ly/43tCPTJ

Publication of research in @SciReports in collaboration w/ @bch_rc on highly selective, non-competitive, & orally administered PAD4 #inhibitors that demonstrated efficacy in 2 animal models of RA & supports the MOA of inhibition via #invitro studies. See: jubilanttx.com/pressreleasede…

Members of the Jubilant team are attending @AACR this month to present on JBI-778, our novel brain-penetrant small molecule PRMT5 inhibitor for the treatment of cancer. Dr. Sivanandhan, VP & Head, Biology, will lead the presentation. Abstract: bit.ly/40b8maq

Today marks 75 years of #WorldHealthDay, a day dedicated to furthering health for all. Jubilant Therapeutics is committed to improving public health through the continued development of our patient-centric research and development.

We present data on our brain penetrant small molecule PRMT5 inhibitor JBI-778 for the treatment of cancer @AACR Annual Meeting in Orlando on 4/19. JBI-778 penetrated the brain in all animal species tested & highly efficacious in orthotopic glioma models. bit.ly/40b8maq

If you missed the live coverage of our @Baird Biotech Discovery Series fireside chat last week, a replay of the discussion is available on our website. Leaders discussed our lead indication strategy, targeting broad subsets, and the potential of PRMT5. bit.ly/3NYuLmu

Jubilant Therapeutics’ PAD4 inhibitor, JBI-1044, is showing positive data in preclinical models of #psoriasis, #lungfibrosis including #COVID19 ARDS and has the opportunity for broader application in other autoimmune disorders such as #SLE and #DVT. #AutoimmuneAwarenessMonth

Members of the Jubilant executive team and board of directors participated in @Baird Biotech Discovery Series Fireside Chat this afternoon. Thank you to our Baird host and moderator for a great discussion about our pipeline of therapeutics! To listen: bit.ly/3NYuLmu